Holen Sie sich die Stockscreener-App
12.58
11.17%
-1.61
Schlusskurs vom Vortag:
$14.19
Offen:
$14.19
24-Stunden-Volumen:
132.35K
Relative Volume:
0.09
Marktkapitalisierung:
$343.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-49.81M
KGV:
-5.8349
EPS:
-2.156
Netto-Cashflow:
$-42.93M
1W Leistung:
+2.90%
1M Leistung:
+82.95%
6M Leistung:
+416.60%
1J Leistung:
+216.71%
1-Tages-Spanne:
$12.58
$14.20
1-Wochen-Bereich:
$11.73
$15.18
52-Wochen-Spanne:
$1.60
$15.18
Alto Neuroscience Inc Stock (ANRO) Company Profile
Firmenname
Alto Neuroscience Inc
Sektor
Branche
Telefon
773-255-5012
Adresse
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Vergleichen Sie ANRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
12.69 | 438.60M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.50 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.12 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
828.79 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.35 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-29 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-23 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-09-03 | Eingeleitet | Wedbush | Outperform |
| 2024-02-27 | Eingeleitet | Jefferies | Buy |
| 2024-02-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-27 | Eingeleitet | Stifel | Buy |
| 2024-02-27 | Eingeleitet | TD Cowen | Outperform |
| 2024-02-27 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Alto Neuroscience Inc Aktie (ANRO) Neueste Nachrichten
Quantitative breakdown of Alto Neuroscience Inc. recent move2025 Support & Resistance & Daily Risk Controlled Trade Plans - newser.com
Is Alto Neuroscience Inc. stock gaining market shareJuly 2025 Trends & Low Risk Profit Maximizing Plans - newser.com
Can Alto Neuroscience Inc. hit a new high this monthQuarterly Profit Report & AI Powered Market Entry Ideas - newser.com
Price action breakdown for Alto Neuroscience Inc.Portfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Is Alto Neuroscience Inc. stock a buy during volatile marketsTrade Ideas & AI Optimized Trading Strategy Guides - newser.com
Can Alto Neuroscience Inc. stock outperform in 2025 bull marketEarnings Summary Report & Long-Term Capital Growth Ideas - newser.com
Why Alto Neuroscience Inc. stock gets analyst attentionPortfolio Profit Report & Real-Time Buy Zone Alerts - newser.com
How risky is Alto Neuroscience Inc. stock now2025 Earnings Impact & Reliable Trade Execution Plans - newser.com
When is the best time to exit Alto Neuroscience Inc.Dollar Strength & Short-Term Trading Alerts - newser.com
Chart based exit strategy for Alto Neuroscience Inc.Market Weekly Review & Fast Moving Market Watchlists - newser.com
Relative strength of Alto Neuroscience Inc. in sector analysisQuarterly Earnings Summary & Reliable Price Breakout Signals - newser.com
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Will Alto Neuroscience Inc. stock recover faster than marketStock Surge & Scalable Portfolio Growth Ideas - newser.com
Can Alto Neuroscience Inc. stock test all time highs2025 Top Decliners & Technical Pattern Recognition Alerts - newser.com
What data driven models say about Alto Neuroscience Inc.’s futureMarket Risk Summary & Daily Profit Focused Screening - newser.com
What the charts say about Alto Neuroscience Inc. todayDollar Strength & Real-Time Buy Signal Alerts - newser.com
Can Alto Neuroscience Inc. stock sustain free cash flow growth2025 Performance Recap & Free Technical Confirmation Trade Alerts - newser.com
What indicators show strength in Alto Neuroscience Inc.2025 Retail Activity & Stock Market Timing Techniques - newser.com
What makes Alto Neuroscience Inc. stock attractive to growth funds2025 Major Catalysts & Technical Entry and Exit Tips - newser.com
COMMODORE CAPITAL LP Acquires Significant Stake in Alto Neuroscience Inc - GuruFocus
Will Alto Neuroscience Inc. stock maintain growth storyMarket Performance Report & Daily Market Momentum Tracking - newser.com
Is Alto Neuroscience Inc. trending in predictive chart modelsWatch List & Daily Stock Trend Watchlist - newser.com
How to track smart money flows in Alto Neuroscience Inc.Trade Volume Summary & Verified Swing Trading Watchlist - newser.com
Why retail investors pile into Alto Neuroscience Inc. stock2025 Institutional Moves & Consistent Growth Stock Picks - newser.com
Will Alto Neuroscience Inc. stock go up soon2025 Risk Factors & Daily Profit Maximizing Tips - newser.com
What institutional flow reveals about Alto Neuroscience Inc.Weekly Trade Report & Safe Capital Growth Plans - newser.com
Risk adjusted return profile for Alto Neuroscience Inc. analyzedJuly 2025 Analyst Calls & Weekly High Momentum Picks - newser.com
Why institutional investors increase stakes in Alto Neuroscience Inc. stockJuly 2025 Decliners & Community Trade Idea Sharing Platform - newser.com
What market sentiment indicators show for Alto Neuroscience Inc. stockWeekly Trend Recap & AI Driven Price Predictions - newser.com
What MACD signals say about Alto Neuroscience Inc.2025 Market Outlook & Community Supported Trade Ideas - newser.com
Volume spikes in Alto Neuroscience Inc. stock – what they mean2025 Historical Comparison & Stock Market Timing Techniques - newser.com
Alto Neuroscience’s ALTO-100 Study: A Potential Game-Changer for Bipolar Disorder Treatment? - TipRanks
Biotech to Fast Track Phase 3 Depression Trial - streetwisereports.com
Buy Recommendation for Alto Neuroscience Driven by Promising ALTO-207 Acquisition and Strategic Financial Backing - TipRanks
Is Alto Neuroscience Inc. stock cheap compared to fundamentalsEarnings Overview Summary & Advanced Technical Signal Analysis - newser.com
Alto Neuroscience’s ALTO-101 Study: A Potential Game-Changer for Schizophrenia Treatment? - MSN
Finanzdaten der Alto Neuroscience Inc-Aktie (ANRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):